MarketCap
Facebook
X
Telegram
BioXcel Therapeutics Financial Ratios 2025-2011 | BTAI
Brief overview of BioXcel Therapeutics's multiples and efficiency
The review covers five available annual periods spanning 2020 to 2025.
The valuation comparison uses P/S 23.96x (median 23.96x), P/B 1.03x (median 2.14x). On average, this basket is 26.1% below its own five-year medians. The market values the business at a discount to recent history.
Capital efficiency is characterized by ROE 73.2%, ROA -155.6%, ROCE 52.9%. Current return ratios are negative, materially weakening the fundamental profile.
Price, earnings and growth produce a PEG of 0.14x. A value below one indicates moderate pricing relative to expected growth.
Overall assessment
BioXcel Therapeutics's valuation is lower, but weak quality metrics call for caution. Recovery in earnings and capital returns is the key catalyst.
Annual Financial Ratios BioXcel Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.2 | -0.1 | -0.0 | -0.5 | -4.4 | -12.2 | -8.6 | -4.1 | - | - | - | - | - | - | - |
P/S |
24.0 | 2.4 | 3.7 | 209.9 | - | 41328144.2 | - | - | - | - | - | - | - | - | - |
EPS |
-5.7 | -23.5 | -98.3 | -5.9 | -4.0 | -3.8 | -2.0 | -1.3 | -0.5 | - | - | - | - | - | - |
EV (Enterprise Value) |
127 M | 107 M | 70.1 M | 14.1 M | 260 M | 804 M | 261 M | 41.9 M | 1.45 M | 331 K | - | - | - | - | - |
EBITDA per Share |
-4.11 | -26.4 | -94.2 | -5.69 | -4.04 | -3.79 | -2.05 | -1.37 | - | - | - | - | - | - | - |
EV/EBITDA |
-2.5 | -1.6 | -0.4 | -0.1 | -2.4 | -9.6 | -7.5 | -1.9 | - | - | - | - | - | - | - |
PEG |
-0.0 | -0.0 | -0.0 | - | - | 0.14 | 0.16 | 0.01 | - | - | - | - | - | - | - |
P/B |
-0.2 | -0.1 | -0.1 | 1.0 | 2.1 | 4.9 | 10.6 | 2.1 | - | - | - | - | - | - | - |
P/CF |
-0.3 | -0.1 | -0.0 | -0.6 | -5.8 | -15.1 | -10.1 | -5.8 | - | - | - | - | - | - | - |
ROE % |
73.22 | 64.02 | 316.86 | -215.90 | -48.24 | -39.75 | -122.58 | -49.55 | - | - | - | - | - | - | - |
ROA % |
-155.62 | -155.46 | -242.94 | -80.52 | -44.66 | -37.36 | -90.59 | -44.25 | - | - | - | - | - | - | - |
ROCE % |
52.86 | 72.23 | 304.00 | -207.94 | -48.24 | -39.55 | -120.33 | -51.33 | - | - | - | - | - | - | - |
Current Ratio |
0.3 | 0.3 | 0.6 | 1.6 | 13.5 | 18.3 | 4.0 | 9.3 | - | - | - | - | - | - | - |
DSO |
103.5 | 16.3 | 42.2 | 120.7 | - | - | - | - | - | - | - | - | - | - | - |
DIO |
1559.0 | 227.4 | 575.9 | 18113.1 | - | - | - | - | - | - | - | - | - | - | - |
DPO |
34153.1 | 2524.5 | 3459.1 | 136017.2 | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
1662.5 | 243.7 | 618.1 | 18233.8 | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
-32490.6 | -2280.9 | -2841.0 | -117783.4 | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios BioXcel Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.54 | -2.18 | -2.45 | -1.5 | - | -5.15 | -3.3 | -0.87 | - | -1.72 | -1.83 | - | - | -1.49 | -1.35 | -1.12 | - | -0.96 | -1.11 | -1.08 | - | -1.07 | -1.06 | -0.79 | - | -0.57 | -0.54 | -0.46 | - | -0.31 | -0.19 | -0.37 | - | -0.1 | -0.06 | -0.06 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.43 | -1 | -2.01 | -2.07 | - | -5.74 | -6.84 | -0.78 | - | -1.65 | -1.79 | - | - | -1.39 | -1.29 | -1.12 | - | -0.96 | -1.1 | -1.07 | - | -1.07 | -1.05 | -0.79 | - | -0.57 | -0.54 | -0.47 | - | -0.33 | -0.21 | -0.37 | - | -0.1 | -0.06 | -0.06 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
72.65 | 76.57 | 52.97 | 72.18 | 64.13 | 188.46 | -740.08 | -850.86 | -887.88 | -920.80 | -1068.06 | -171.68 | -72.07 | -82.99 | -60.40 | -51.59 | -35.37 | -47.35 | -46.79 | -43.68 | -29.55 | -63.08 | -82.60 | -99.03 | -91.81 | -104.38 | -78.63 | -58.14 | -31.36 | 62.02 | 132.12 | 193.78 | 204.79 | 93.38 | 57.54 | 53.87 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-199.52 | -190.14 | -133.81 | -91.95 | -73.15 | -123.41 | -133.69 | -138.08 | -105.53 | -120.71 | -85.36 | -47.16 | -47.16 | -57.42 | -50.17 | -48.16 | -33.25 | -44.50 | -43.98 | -40.94 | -27.77 | -52.55 | -64.58 | -74.63 | -67.85 | -79.07 | -61.24 | -47.80 | -28.00 | -95.68 | -126.15 | -158.25 | -148.41 | -67.68 | -41.70 | -39.04 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
51.61 | 59.78 | 67.06 | 85.73 | 74.53 | 193.46 | -718.22 | -772.20 | -805.60 | -827.69 | -962.85 | -69.02 | -69.02 | -79.94 | -59.56 | -51.60 | -35.37 | -47.35 | -46.81 | -43.73 | -29.61 | -63.57 | -83.69 | -100.91 | -93.65 | -106.82 | -81.20 | -60.11 | -32.53 | 60.85 | 131.55 | 193.77 | 204.79 | 93.38 | 57.54 | 53.87 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
0.2 | 0.3 | 0.2 | 0.3 | 0.3 | 0.4 | 0.5 | 0.5 | 0.6 | 0.7 | 1.0 | - | 1.6 | 2.1 | 3.0 | 12.4 | 13.5 | 16.6 | 20.5 | 14.7 | 16.6 | 16.6 | 16.6 | 16.6 | 3.8 | 3.8 | 3.8 | 3.8 | 9.3 | 9.3 | 9.3 | 9.3 | 0.6 | 0.6 | 0.6 | 0.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
47.8 | 7.9 | 56.3 | 71.2 | - | 173.8 | 49.2 | 35.2 | - | 156.0 | 43.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
154.6 | 4002.6 | 489.5 | 4305.0 | - | 164.0 | 3767.0 | 2526.5 | - | 351.4 | 3378.0 | - | - | 11626.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
5243.3 | 136742.3 | 13705.4 | 102460.7 | - | 1097.5 | 22426.9 | 17607.8 | - | 1949.0 | 19659.1 | - | - | 49328.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | 4002.6 | 561.6 | - | - | 337.7 | 3473.8 | - | - | 507.4 | - | - | - | 11626.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | -132739.7 | -13374.1 | - | - | -759.8 | -16328.9 | - | - | -1441.7 | - | - | - | -37702.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company BioXcel Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
